With a proglucagon probe, Northern blot analysis
(Fig. 3B) showed
bands with molecular weights varying between 1.8 and 2.0 kb, as well as
a 1.5-kb band. Additionally, some blots showed a weaker band of 1 kb
and of 4.6 kb. The 1.5-kb band corresponds to the expected size of the
pre- proglucagon mRNA (1576 bp). Therefore, results concerning the
intensity of the 1.5-kb band are given in detail. One day of positive
lens wear increased glucagon mRNA levels significantly
(
P = 0.045, paired Student’s
t-test). After
6 hours of positive lens wear, the glucagon mRNA level was increased to
158% ± 27% (
n = 4), and it was even higher after 1-day
treatment with +7-D spectacles (197% ± 105%,
n = 8).
Glucagon levels reached control levels after 7 days of treatment with
positive lenses (data not shown). There was a trend toward a decrease
in the amount of glucagon mRNA during treatment with negative lenses
for 6 hours (71% ± 13%, result not shown,
n = 3) and 1
day (67% ± 32%,
n = 7) that did not achieve statistical
significance in comparison with the respective controls (1-day −7-D
lens treatment versus control,
P = 0.067, paired
Student’s
t-test). Goggle wear did not influence glucagon
mRNA level consistently (6 hours, 107% ± 15%, result not shown,
n = 3; 1 day, 100% ± 33%,
n = 7).
Although glucagon has been shown to act as a
neurotransmitter/neuromodulator in the central nervous
system,
14 its role in the retina is less clear. Treatment
of chicken retina with glucagon increased the cyclic adenosine
monophosphate (cAMP) level.
15 Other studies
16 in the turtle retina led to the conclusion that glucagonergic amacrine
cell may provide OFF-modulation in interactions between the ON- and
OFF-center visual pathways. From our Northern blot analysis studies, it
can be concluded that glucagon is one promising candidate for a
messenger carrying the sign of defocus information, because mRNA levels
increased significantly after positive lens wear and showed at least a
trend toward a decrease after negative lens wear (
P =
0.067). To further strengthen the possible role of glucagon, we are
currently conducting pharmacologic studies using glucagon antagonists
and agonists.
The authors thank Andy Fischer and Bill Stell, University
of Calgary Faculty of Medicine, Alberta, Canada, for continuous
discussions and insight into their most recent data.